AbbVie reports Q2 non-GAAP EPS of $3.65 and revenue of $16.99B, exceeding analyst expectations.
AbbVie posted second-quarter non-GAAP earnings per share of $3.65, beating estimates by $0.04, as revenue rose 10.2% year-over-year to $16.99 billion. The company surpassed revenue expectations by $230 million.
Global net revenues from AbbVie’s immunology portfolio reached $8.786 billion, up 15.1% on a reported basis and 14.6% operationally. The growth was driven by strong demand for key immunology products.
The results reflect continued momentum in AbbVie’s core therapeutic areas, offsetting challenges in other segments.